NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical firm pioneering the invention, growth, and commercialization of allogeneic, off-the-shelf, invariant pure killer T (iNKT) cell therapies to deal with most cancers and different immune-mediated ailments, at this time introduced two poster shows on the Society for Immunotherapy of Most cancers’s (SITC) 29th Annual Assembly on November 6-10, 2024, in Houston, Texas. The shows will showcase new preclinical information from MiNK’s iNKT cell applications, agenT-797 and PRAME-TCR.
Presentation Particulars
AgenT-797 cell remedy may be mixed with next-generation immune checkpoint inhibitors (ICI) and / or bi-specific engagers to enhance anticancer response
Summary Quantity: 753
Date: Friday, November 8th
PRAME-TCR iNKT cell remedy: Alternative for best-in-class off-the-shelf strong tumor remedy focusing on PRAME
Summary Quantity: 374
Session Date: Saturday, November 9th
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical firm pioneering the invention, growth, and commercialization of allogeneic invariant pure killer T (iNKT) cell therapies to deal with most cancers and different immune-mediated ailments. MiNK is advancing a pipeline of each native and subsequent technology engineered iNKT applications, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf supply. The corporate is headquartered in New York, NY. For extra data, go to https://minktherapeutics.com/ or @MiNK_iNKT. Data that could be necessary to buyers might be routinely posted on our web site and social media channels.
Ahead Wanting Statements
This press launch accommodates forward-looking statements which might be made pursuant to the protected harbor provisions of the federal securities legal guidelines, together with statements relating to the therapeutic and healing potential of agenT-797 and iNKT cells the mechanism of motion, efficiency and security, interim or top-line information, together with statements relating to scientific information of agenT-797, the anticipated advantages of agenT-797 and scientific growth plans and timelines. These forward-looking statements are topic to dangers and uncertainties that might trigger precise outcomes to vary materially. These forward-looking statements are topic to dangers and uncertainties, together with the components described underneath the Danger Elements part of the newest Type 10-Ok filed with the SEC. MiNK cautions buyers to not place appreciable reliance on the forward-looking statements contained on this launch. These statements communicate solely as of the date of this press launch, and MiNK undertakes no obligation to replace or revise the statements, aside from to the extent required by regulation. All forward-looking statements are expressly certified of their entirety by this cautionary assertion.
Investor Contact
917-362-1370
Media Contact
781-674-4428